Time & location: 11:00AM, Virtual
Nature.com Webcasts
8AM PST | 11AM EST | 4PM GMT | 5PM CET
Compared to tissue-based biomarkers, blood-based biomarkers have many advantages including lower risks to patients, lower cost, and easier collection along the continuum of care, including at the start of treatment, in the setting of response, and at the time of progression. Many proteins of interest in cancer biology can be detected in plasma. These include inflammatory, immune, and tumor-related growth factors that have been described to mediate resistance to various targeted therapeutics. However, many cytokines and growth factors circulate at very low levels and are often difficult to detect using standard ELISA technologies. Utilizing ultrasensitive technologies, we now have the ability to systematically evaluate low abundance cytokines and growth factors.
Join Dr. Andrew Nixon, Associate Professor in Medicine at Duke University Medical Center as he discusses multiplexing of these ultrasensitive assays and how they allow for the assessment of multiple proteins at lower cost and from less plasma volume than traditional ELISA formats.
Because ELISA techniques are also readily adapted into clinical diagnostics, any potential findings in plasma are highly actionable, both diagnostically and therapeutically.
Related Posts
Underdiagnosis of Alzheimer’s disease pathology in patients with cardiovascular disease
Decoding Neurodegeneration: High-plex Spatial Proteomics Reveal Distinct Cell Phenotypes and Pathological Signatures in Parkinson’s and Alzheimer’s Disease
In this webinar, Dr. Birgitt Schuele, Associate Professor (Research) of Pathology at Stanford University, showcases how ultrahigh-plex spatial proteomics is being used to uncover distinct cell phenotypes and pathological signatures…
Understanding the Brain: Advancing Neurodegeneration Research with Ultrahigh-Plex Spatial Proteomics
In this webinar, learn how ultrahigh-plex spatial phenotyping has been applied to neurodegenerative disease research.
p-Tau 205 and p-Tau 212: Emerging Biomarkers for Alzheimer’s Disease Research
Spatial Awareness: AI-powered Profiling of Trillions of Immune Cell Distribution Data Points Reveals Key Predictors of Cancer Recurrence Risk
This webinar highlights a groundbreaking study recently published as a Nature cover story (April 2025). Dr. Joe Yeong will describe how a pre-designed analytical framework—driven by well-defined clinical and scientific…
Multimodal Single-Cell Spatial Transcriptomics and Proteomics to Uncover the Biological Processes Driving Immunotherapy Response and Resistance in Renal Cancer
In this webinar, Dr. Anne-Laure Cattin from the Cancer Dynamics Laboratory at The Francis Crick Institute in London, will share her research on kidney cancer, focusing on the integration of…
Tertiary Lymphoid Structures in Cancer Immunotherapy: Insights and Perspectives
Tertiary lymphoid structures (TLS) have emerged as critical components of the tumor microenvironment, influencing immune responses and clinical outcomes in cancer.
